Literature DB >> 22136834

Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important.

Paxton V Dickson1, Thereasa A Rich, Yan Xing, Gilbert J Cote, Huamin Wang, Nancy D Perrier, Douglas B Evans, Jeffrey E Lee, Elizabeth G Grubbs.   

Abstract

BACKGROUND: Controversy exists regarding the role and extent of operation for patients with multiple endocrine neoplasia type 1 (MEN1) and hypergastrinemia.
METHODS: An institutional MEN1 database was reviewed to identify patients with evidence of hypergastrinemia. The relationship of extent of resection to achievement of eugastrinemia was evaluated.
RESULTS: Operation was performed in 20 patients with MEN1 and hypergastrinemia with a median follow-up of 71 months. Duodenal gastrinomas were identified in 85% of patients who underwent duodenal evaluation. Nodal metastases were identified in 80%. Patients who underwent anatomic regional lymph node dissection (RLND) had a median of 16 nodes removed, vs 1 in patients who did not undergo a formal regional lymphadenectomy. Eugastrinemia was achieved in 12 patients (60%), and 8 (40%) had persistent hypergastrinemia. Compared with patients with persistent hypergastrinemia, patients rendered eugastrinemic more often underwent duodenal evaluation (11/12 vs 2/8; P = .01) and RLND (11/12 vs 3/8; P = .03); there was no relationship between pancreatic resection and achievement of eugastrinemia (P = .32).
CONCLUSION: For patients with MEN1-associated hypergastrinemia selected for operative treatment, a strategy including duodenal evaluation and anatomic regional lymphadenectomy is associated with long-term eugastrinemia. In contrast, the extent of pancreatic resection should be dictated by the extent and distribution of pancreatic neuroendocrine neoplasms, rather than by the presence of hypergastrinemia.
Copyright © 2011. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136834     DOI: 10.1016/j.surg.2011.09.028

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  [MEN1 gastrinoma: routine duodenal exploration!].

Authors:  H Dralle
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

2.  Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Authors:  S Chiloiro; F Lanza; A Bianchi; G Schinzari; M G Brizi; A Giampietro; V Rufini; F Inzani; A Giordano; G Rindi; A Pontecorvi; L De Marinis
Journal:  Endocrine       Date:  2017-05-31       Impact factor: 3.633

Review 3.  Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.

Authors:  Kazuhiro Hanazaki; Akihiro Sakurai; Masaya Munekage; Kengo Ichikawa; Tsutomu Namikawa; Takehiro Okabayashi; Masayuki Imamura
Journal:  Surg Today       Date:  2012-10-19       Impact factor: 2.549

Review 4.  Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome.

Authors:  Francesco Tonelli; Francesco Giudici; Gabriella Nesi; Giacomo Batignani; Maria Luisa Brandi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

5.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

6.  Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort.

Authors:  Dirk-Jan van Beek; Sjoerd Nell; Wessel M C M Vorselaars; Bert A Bonsing; Casper H J van Eijck; Harry van Goor; Elisabeth J Nieveen van Dijkum; Cornelis H C Dejong; Gerlof D Valk; Inne H M Borel Rinkes; Menno R Vriens
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

7.  Gastroenteropancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Francesco Tonelli; Francesco Giudici; Francesca Giusti; Maria Luisa Brandi
Journal:  Cancers (Basel)       Date:  2012-05-07       Impact factor: 6.639

8.  Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.

Authors:  C Romei; E Pardi; F Cetani; R Elisei
Journal:  J Oncol       Date:  2012-11-08       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.